A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Abroad (travel likely)RecruitingPHASE2
Conditions
Peritoneal Carcinomatosis · Ovarian Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (Hye Sook Chon, MD, PhD)UZ Leuven, Leuven, Belgium
Contact: Study coordinator (Els Van Nieuwenhuysen, MD, PhD)Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
Contact: Study coordinator (Anna Fagotti, MD, PhD)The Norwegian Radiumhospital, Oslo, Norway
Contact: Study coordinator (Yun Wang, MD, PhD)Hospital Universitari de Bellvitge, Barcelona, Spain
Contact: Study coordinator (Jordi Ponce, MD, PhD)Clinica Universidad de Navarra, Madrid, Spain
Contact: Study coordinator (Luis M Chiva, MD, PhD)Clinica Universidad de Navarra, Pamplona, Spain
Contact: Study coordinator (Luis M Chiva, MD, PhD)Hospital Universitari i Politècnic La Fe, Valencia, Spain
Contact: Study coordinator (Victor Lago Leal, MD, PhD)Imperial College Healthcare NHS Trust, London, United Kingdom
Contact: Study coordinator (Christina Fotopoulou, MD, PhD)University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Contact: Study coordinator (David Constable-Phelps, MD, PhD)